Genetic factors involved in the bioavailability of tomato carotenoids

Charles Desmarchelier,^{1*} Jean-François Landrier,¹ Patrick Borel^{1*}

¹C2VN, Aix Marseille Univ, INRA, INSERM, Marseille, France

*Correspondence: charles.desmarchelier@univ-amu.fr, Tel.: +33 4 91 32 42 82;
patrick.borel@univ-amu.fr, Tel.: +33 4 91 32 42 77

Abbreviations: ABCA1 (ATP binding cassette subfamily A member 1); ABCB1 [ATP-binding cassette, sub-family B (MDR/TAP), member 1]; APOB (apolipoprotein B); BCO1 (β -carotene oxygenase 1); BCO2 (β -carotene oxygenase 2); CD36 (CD36 molecule); ELOVL2 (ELOVL fatty acid elongase 2); ISX (intestine specific homeobox); LIPC (lipase C, hepatic type); MTTP (microsomal triglyceride transfer protein); *SCARB1* (gene)/SR-BI (protein) (scavenger receptor class B, member 1); SNP (single nucleotide polymorphism).

ABSTRACT

Purpose of review: To provide an update on the genetic factors recently associated with the interindividual variability of tomato carotenoid bioavailability.

Recent findings: Several clinical studies have demonstrated that the main carotenoids found in tomatoes (lycopene, phytoene, phytofluene, β -carotene, lutein) all display relatively large interindividual variabilities of their bioavailability, with CVs >70%. The bioavailability of the parent molecules, and the blood/tissue appearance of their metabolites, is modulated by numerous proteins, involved in intestinal absorption and metabolism, blood lipoprotein transport or tissue uptake. Several single nucleotide polymorphisms have been associated with the interindividual variability of lycopene, lutein and β -carotene bioavailability, with six genes consistently shared between the three carotenoids, and in particular one SNP in *ELOVL fatty acid elongase 2*. The effects of the genetic variants taken separately are relatively low, *i.e.* each variant is usually associated with only a few percent of the bioavailability, but multivariate analysis suggest that the additive effect of several genetic variants can explain a significant fraction of tomato carotenoid bioavailability.

Summary: Additional studies are needed to improve our knowledge of the genetic determinants of tomato carotenoid bioavailability but progress in this field could one day allow nutritionists to provide more personalized dietary recommendations.

Keywords: Single nucleotide polymorphism, beta-carotene, lycopene, lutein, absorption.

INTRODUCTION

Tomatoes, whether consumed raw or processed, are an important component of many human diets. For example, in the US population, they constitute the second most consumed vegetable, only topped by potatoes [1]. Their consumption has been associated with a decreased risk to develop several chronic diseases, such as cardiovascular diseases [2], certain types of cancers [3] or age-related macular degeneration [4]. Tomatoes contain many potential health promoting compounds, *e.g.* minerals, vitamins or phytochemicals such as polyphenols and carotenoids [5]. Among these components, carotenoids have received considerable interest and results from many *in vitro*, animal, clinical and association studies point at their significant contribution to the observed health benefits of tomato consumption (see [6] for review). Carotenoids have been assumed to exert their biological effects through their well characterized antioxidant properties [7] or pro-vitamin A activities for some (mainly β -carotene, α -carotene and β -cryptoxanthin). However, it is now established that carotenoids, as parent molecules or via the many metabolites they can generate [8, 9], also exhibit biological activities independent of their antioxidant properties, *e.g.* as modulators of inflammation [10-13] or nuclear receptor ligands [14, 15]. Lycopene is the carotenoid found at the highest concentration in tomatoes, giving them their usual red colour, but other carotenoids are also found in significant amounts, *i.e.* α -, β -, δ -, γ -carotene, lutein, and the colourless carotenoids phytoene and phytofluene [5, 16]. It should be stressed that the tomato carotenoid profile, including their isomeric profile [17], is highly variable, depending on factors such as cultivar, environment, agronomic practices, stage of ripeness, or conditioning, which might in turn also modify the related health properties. Carotenoid concentration at their site of action in the human body depends on both their intake and their bioavailability. Carotenoid bioavailability is a complex phenotype, involving many steps and, as a consequence, it is highly variable. Indeed, many factors are involved, from characteristics of the diet, *e.g.* amount of fat, of fibres, food processing, to host

related features, *e.g.* sex, age, pathologies or genetic characteristics [18, 19]. The early observation of a relatively high interindividual variability in β -carotene bioavailability [20] together with the more recent identification of several proteins involved in the intestinal absorption of carotenoids [21] has led to hypothesize that genetic variations in these genes could partly explain this variability. This field of research has lately received an increased interest, due to the emergence of affordable genotyping technologies, and several SNPs have been shown to be associated with the variability of tomato carotenoid bioavailability, opening the possibility for more personalized dietary recommendation that would improve the health benefits of tomato consumption.

PROTEINS INVOLVED IN TOMATO CAROTENOID BIOAVAILABILITY

Before discussing the genetic variations that have been associated with tomato carotenoid bioavailability, it is important to describe the successive steps involved, from their extraction from the food matrix during digestion to their distribution to their site of action, with an emphasis on the proteins implicated. Detailed descriptions can be found in several recent reviews [18, 19, 22] and we will here only focus on the more recent developments in this field. Carotenoids are lipids and their fate in the gastrointestinal tract during digestion, their absorption by enterocytes and their distribution in the circulation hence share common mechanisms with other lipid molecules, such as fat-soluble vitamins.

The first step involved in carotenoid bioavailability is their micellization, *i.e.* their transfer from the food matrix to mixed micelles. Digestive enzymes participate in this process by contributing to the degradation of the food matrix and indeed, pancreatic lipase, encoded by *PNLIP*, has been shown to facilitate the transfer of carotenoids from emulsified lipid droplets towards mixed micelles [23]. It should be emphasized that the efficiency of this process is relatively low, especially for lycopene where bioaccessibility values, *i.e.* percent of

incorporation in micelles, reported are typically $\leq 2\%$ [24], and that consequently, a large fraction of ingested carotenoids are not absorbed in the small intestine. They hence reach the colon but data regarding interaction with the gut microbiota is missing [25] and the fate of metabolites that could be produced remains largely unknown.

The second step is the uptake of bioaccessible carotenoids by enterocytes. This process was long thought to occur by simple passive diffusion only but several proteins located at the apical membrane, at least temporarily, have been shown to participate in the facilitated diffusion of carotenoids [21]. Scavenger receptor class B member 1 (SR-BI), which is encoded by *SCARB1*, participates in the uptake of provitamin A carotenoids [26, 27], lutein [28], zeaxanthin [29], lycopene [30], phytoene and phytofluene (data submitted for publication). CD36 molecule (CD36) facilitates provitamin A carotenoid uptake [26] and could also facilitate lycopene uptake [31] while NPC1 like intracellular cholesterol transporter 1 could be involved in the uptake of lutein [32]. The precise mechanism(s) of carotenoid uptake in the enterocyte is still not known and it has recently been suggested that some of these proteins might actually interact indirectly by promoting the assembly and secretion of chylomicrons, thereby increasing their gradient between the intestinal lumen and the enterocyte [33, 34].

Following their apical uptake, carotenoids can be metabolised by two enzymes, β -carotene oxygenase 1 (BCO1) [35] and β -carotene oxygenase 2 (BCO2) [36], which differ in their substrates, products and cellular localization. BCO1 is a cytosolic enzyme which catalyses the oxidative central cleavage of provitamin A carotenoids, yielding at least one retinal molecules (2 for β -carotene), but also that of beta-apocarotenals and lycopene [37]. BCO2 is a mitochondrial inner membrane protein which cleaves carotenoids eccentrically and yields apo-carotenals. Overall, BCO1 is assumed to be the main cleaving enzyme for provitamin A carotenoids while BCO2 is assumed to favour that of non-provitamin A carotenoids [38]. Nevertheless, this does not apply to lycopene since its cleavage seems to depend on its

isomerisation, which mostly takes place in the enterocyte [39]. Indeed, the all-*trans* isomer has been shown to be only cleaved by BCO1 [37, 40, 41], while the 5-*cis* and 13-*cis* isomers are only cleaved by BCO2 [42, 43]. These two enzymes are not solely expressed in enterocytes but it has been shown that more than $\approx 70\%$ β -carotene conversion occurs in the small intestine [44, 45]. Interestingly, both *BCO1* and *SCARB1* are under the regulation of an intestinal transcription factor named intestine specific homeobox (ISX): when cellular all-*trans* retinoic acid concentration increases, ISX is activated and in turns represses *BCO1* and *SCARB1* expression, which decreases carotenoid uptake and processing and ultimately retinoic acid production, thus constituting a negative feedback loop regulation of intracellular retinoic acid concentration [29]. Interestingly, a SNP in the ISX binding site in the *BCO1* promoter was found to be associated with decreased conversion rates of β -carotene by 50% and increased fasting blood concentrations of β -carotene [46]. Although this mechanism was first described for β -carotene [47], which yields two retinal molecules upon BCO1 cleavage, it has also been demonstrated for zeaxanthin [29], a xanthophyll, and probably applies to other carotenoids. The respective contribution of circulating retinol vs newly absorbed vitamin A or carotenoids to intracellular enterocyte retinoic acid concentration is not known. Furthermore, blood retinol concentration is homeostatically regulated and only poorly reflects total vitamin A status. Thus, whether this mechanism links vitamin A status to carotenoid bioavailability remains to be confirmed. Overall, these proteins play crucial roles in carotenoid absorption and thus genetic variations in their encoding genes are good candidates to explain the high interindividual variability in carotenoid bioavailability. Moreover, we hypothesize that these genetic variations could also influence the profile of carotenoid metabolites generated upon carotenoid intake and hence modify some of their health properties, but this remains to be demonstrated.

In order to reach the circulation, carotenoids, or their metabolites, must be secreted at the basolateral side of the enterocyte. No intracellular transport protein has been identified yet, so

the mechanism by which the parent molecules, which are highly apolar, as well as some of the more apolar metabolites, cross the enterocyte cytosol remains unknown. Native carotenoids are assumed to be mostly secreted with chylomicrons into the lymph, thus following the fate of other newly absorbed lipids. This process likely involves enzymes/apolipoproteins responsible for the assembly of chylomicrons, *e.g.* microsomal triglyceride transfer protein (MTP), apoA-IV, secretion associated Ras related GTPase 1B (SAR1B) and apoB48 (encoded by *APOB*) [48]. Nevertheless, secretion in intestinal HDL via the ATP binding cassette A1 (ABCA1) has also been hypothesized [49]. On the other hands, some of the more polar metabolites (with log P values less than 5) may be secreted to the portal vein and then reach the liver.

Carotenoids secreted in chylomicrons are taken up by the liver via the chylomicron-remnant receptors, *i.e.* the LDL-receptor (LDLR), the LDL-receptor related protein 1 (LRP1), and the heparan sulfate proteoglycans (HSPGs) [50]. The fate of carotenoid metabolites secreted in the portal vein has yet to be studied. Carotenoids that reach the liver via chylomicrons are stored in this organ, eliminated in the bile, or re-secreted into VLDL to be distributed to peripheral tissues. However, it cannot be excluded that a fraction of carotenoids are able to significantly transfer between lipoproteins or to transfer from lipoproteins to tissues during intravascular chylomicron metabolism [51]. Xanthophylls are less apolar than carotenes and are thus found closer to the outer layer of lipoproteins compared to carotenes, thereby facilitating their potential exchange between lipoproteins. In agreement, recent data have shown that xanthophylls are transported mostly in HDL while carotenes are found preferentially in LDL, which result from VLDL metabolism [52].

Regarding further carotenoid distribution, it is hypothesized that only tissues that express the LDL-receptor can take up carotenoids incorporated into LDL. Moreover, it has been shown that CD36, which is able to bind oxidized LDL, is involved in adipose tissue uptake of lycopene and lutein [31], and that SR-BI, which is found in many tissues, is involved in the uptake of

zeaxanthin into the retina. Indeed, it has recently been proposed that HDL-zeaxanthin uptake into the retina is facilitated by SR-BI while that of LDL-lutein is facilitated by the LDL receptor [52], thereby protecting the macula from light-induced damages [53, 54].

GENETIC VARIATIONS ASSOCIATED WITH TOMATO CAROTENOID BIOAVAILABILITY

Many clinical trials have investigated the interindividual variability in the response to carotenoid intake. Although there were many differences in the study designs (food *vs* supplement, carotenoid dose ingested, measurement of carotenoid concentration in tissue *vs* blood, number and characteristics of subjects), they systematically reported a high interindividual variability in carotenoid bioavailability, including with tomato products as a source for carotenoids (see [18] for review).

Genetic variations between individuals have been suggested to explain, at least in part, this phenomenon [18, 19, 55, 56]. Consequently, several studies have aimed to identify genetic variants involved in the variability of the bioavailability of carotenoids (*see Table 1 and Figure 1* for summary of published studies). Several different approaches have been used to estimate carotenoid bioavailability [57], which might yield different results depending on the relative contribution of the proteins involved. We have thus proposed to use the postprandial chylomicron carotenoid concentration as an estimate of carotenoid bioavailability in order to allow for comparison between studies [57].

GENETIC VARIATIONS ASSOCIATED WITH LYCOPENE BIOAVAILABILITY

There are only two studies dedicated to identify genetic variations associated with lycopene bioavailability, using either watermelon juices or tomato puree as a source of lycopene. The first one investigated the association between 2 non-synonymous SNPs in *BCO1* and the plasma

174 lycopene concentration in 23 healthy adults following the consumption of watermelon juices
175 (representing 20 mg lycopene per day) for 3 weeks but no significant association was observed
176 [58]. The second study sought to identify a combination of SNPs associated with tomato
177 lycopene bioavailability, which was estimated by measuring the postprandial chylomicron
178 lycopene response to a test-meal containing tomato puree (representing 9.7 mg all-*trans*
179 lycopene) in 33 healthy male subjects [59]. This study showed that lycopene bioavailability
180 was associated with a combination of 28 SNPs in or near 16 candidate genes. Seven of these
181 genes [*ABCA1*, *lipoprotein lipase*, *insulin induced gene 2*, *solute carrier family 27 member 6*,
182 *hepatic lipase (LIPC)*, *CD36*, and *APOB*] had been associated with the postprandial
183 chylomicron triacylglycerol response in the same group of subjects [60]. Four of these genes
184 were more specifically associated with the variability in lycopene bioavailability. *ABCB1*
185 encodes for the P-glycoprotein, an ATP-dependent drug efflux pump for xenobiotics with broad
186 substrate specificity, highly expressed in enterocytes. The association of P-glycoprotein with
187 postprandial lycopene concentrations suggests that it could participate in the efflux of lycopene
188 back to the intestinal lumen, as was recently shown for vitamin D [61]. *ELOVL2* encodes for
189 ELOVL fatty acid elongase 2 which catalyzes the elongation of eicosapentaenoic acid to
190 docosapentaenoic acid and docosapentaenoic acid to docosahexaenoic acid. Carotenoids are not
191 known substrates for this enzyme but this association could be due to an interaction between
192 omega 3 fatty acid metabolism and carotenoids since eicosapentaenoic acid has been shown to
193 inhibit β -carotene absorption [62]. *MTTP* encodes for the microsomal triglyceride transfer
194 protein, which is involved in the packaging of triacylglycerols within chylomicrons, which
195 carry newly absorbed carotenoids in the circulation. *SOD2* encodes the superoxide dismutase 2
196 that is responsible for converting superoxide by-products to hydrogen peroxide and diatomic
197 oxygen. It was hypothesized that, when this enzyme is not efficient, superoxide by-products are
198 quenched by lycopene, leading to its degradation [63].

200 GENETIC VARIATIONS ASSOCIATED WITH LUTEIN BIOAVAILABILITY

201 There are only two studies dedicated to identify genetic variations associated with lutein
202 bioavailability. Neither used tomatoes or tomato products as a source of lutein since other food
203 sources, *e.g.* spinach, provide higher amounts thereof. In the first one, Yonova-Doing *et al.*
204 measured macular pigment optical density, which is a marker of lutein and zeaxanthin
205 concentration in the macula, in 310 Caucasian female twins aged 20-50 before and after
206 receiving 54 mg lutein and 7.2 mg zeaxanthin daily for 6 months [64]. They found four SNPs
207 to be significantly associated with the change in macular pigment optical density following
208 supplementation, which can be considered as a marker of xanthophyll bioavailability. A SNP
209 in *ABCA1*, possibly due to the role of this membrane protein in lipid influx in the retinal pigment
210 epithelium [65] and/or to enterocyte basolateral secretion of HDL-lutein [49], a SNP in
211 *SCARB1*, a SNP in *fatty acid desaturase 1* and a SNP in *retinal pigment epithelium 65*. Fatty
212 acid desaturase 1 is involved in the conversion of α -linolenic acid to eicosapentaenoic acid,
213 which again suggests an association between omega 3 fatty acid metabolism and carotenoid
214 bioavailability. *Retinal pigment epithelium 65* encodes a protein highly expressed in the retinal
215 pigment epithelium, working as a retinol isomerase of the visual cycle, which is involved in
216 visual pigment regeneration and was recently shown to be responsible for the macular
217 production of *meso*-zeaxanthin from lutein [66]. In the second study, the variability in the
218 postprandial chylomicron lutein response to a test-meal supplemented with 15 mg free lutein
219 was associated with a combination of 29 SNPs in 15 genes in a group of 39 healthy adult men
220 [67]. Seven of these genes (*ABCA1*, *APOA1*, *APOB*, *cordon-bleu WH2 repeat protein like 1*,
221 *hepatic lipase*, *insulin induced gene 2*, *insulin receptor substrate 1*, *lipoprotein lipase*, and
222 *melanocortin 4 receptor*) were previously associated with the interindividual variability in the
223 postprandial chylomicron triglyceride response in the same group of subjects (39). Four genes

were more specifically associated with lutein bioavailability: *ATP-binding cassette, subfamily G, member 2*, *ELOVL2*, *ISX* and *MTTP*. Interestingly, SNPs in the last 3 genes were also associated with lycopene variability. *ATP-binding cassette, subfamily G, member 2* encodes for a breast cancer resistance protein (BCRP), which is a multidrug transporter [68], and this association suggests it could also be involved in lutein transport.

GENETIC VARIATIONS ASSOCIATED WITH BETA-CAROTENE BIOAVAILABILITY

There have been four studies, based on three different trials, investigating the effects of genetic variants on β -carotene bioavailability, although only one used tomato puree as a source, while the others used either a supplement or watermelon juices. Two common nonsynonymous SNPs in *BCOI* have been associated with the postprandial triglyceride-rich lipoprotein β -carotene and retinyl palmitate concentrations following consumption of a meal supplemented with 120 mg β -carotene [69] and also with blood β -carotene concentration following consumption for 3 weeks of a watermelon juice, providing a more nutritional dose of β -carotene (2.5 mg per day) [58]. In a re-analysis of the first trial, 3 SNPs upstream from *BCOI* were associated with β -carotene conversion capacity [70]. In the most recent study, the variability in the postprandial chylomicron β -carotene response to a test-meal containing 100 g tomato puree, providing 0.4 mg β -carotene, was associated with a combination of 25 SNPs in 12 genes [71]. Four genes (*ABCA1*, *APOB*, *hepatic lipase*, *transcription factor 7-like 2*) were previously associated with the interindividual variability in the postprandial chylomicron triglyceride response in the same group of subjects [60], while 8 were more specifically associated with the β -carotene response. Interestingly, a SNP in *ISX* and a SNP in *BCOI* were identified, thereby confirming the key role played by *ISX* in β -carotene bioavailability [46]. The second association of interest was found in *ELVOL2*. Moreover, it should be stressed that the same

SNP in *ELOVL2* that was associated with the variability of lycopene and lutein bioavailability was associated with β -carotene bioavailability.

Overall, six genes (*ABCA1*, *APOB*, *ELOVL2*, *ISX*, *LIPC* and *polycystin 1 like 2*) have been consistently shown to have SNPs associated with the variability in the bioavailability of β -carotene, lutein and lycopene, and in particular the same SNP in *ELOVL2* across all three carotenoids. Furthermore, these results were obtained in the same group of subjects [59, 67, 71].

Although it appears that for some of the associations reported between the variability in carotenoid bioavailability and SNPs, tomatoes or tomato products were not used as a source of carotenoids, we believe these results can be extrapolated to tomatoes or tomato products because the main source of variability in these clinical trials originates from genetic variations. Nonetheless, if the effect of the food matrix on carotenoid bioavailability were to be high, it could potentially not allow the comparison with tomatoes or tomato products.

CONCLUSION

Several genetic variants have now been involved in the variability of the bioavailability of the major carotenoids found in tomatoes and they could explain to some extent the variability observed in the health effects associated with tomato and tomato product consumption. Yet, some carotenoids found in significant amount in tomato and tomato products, such as phytoene and phytofluene, have been completely left out of studies so far although they might also be associated with the health properties of tomatoes and tomato products. We now need clinical studies with more participants (including more ethnic groups) to confirm these promising results. More SNPs/genes should be investigated and other genetic variations (*e.g.* copy number variants) or epigenetic modifications should also be considered. To date, there is no data on the

274 effects of genetic variations on the production and bioavailability of carotenoid metabolites,
275 which could be responsible for some of the health effects conferred by tomatoes. Although a
276 lot of work remains to be done, this field of research is promising, and the results generated will
277 contribute to provide personalized dietary recommendations in order to improve the benefit of
278 tomato consumption.

KEY POINTS

- Tomato carotenoid bioavailability is highly variable and some of this variability is due to genetic differences between individuals.
- Many proteins are involved in the bioavailability of carotenoids and their metabolites.
- Several single nucleotide polymorphisms in the genes encoding these proteins have been associated with the observed interindividual variability in tomato carotenoid bioavailability.
- More studies are needed to predict individual responses to tomato carotenoids and provide personalized dietary recommendations.

ACKNOWLEDGEMENTS

None.

FINANCIAL SUPPORT AND SPONSORSHIP

None.

CONFLICTS OF INTEREST

None.

AUTHOR CONTRIBUTIONS

C. Desmarchelier, J.F. Landrier and P. Borel contributed equally to the writing of this review.

Figure 1. Summary of the genes involved in the variability of tomato carotenoid bioavailability.

Genes displayed are those for which SNPs have been associated with the variability of the bioavailability of lycopene, β -carotene or lutein. Genes in bold letters are those for which SNPs have been associated with the variability of the bioavailability of these three carotenoids.

Table 1. Summary of SNPs associated with tomato carotenoid bioavailability.

SNP	Global MAF ¹	Nearest Gene	Carotenoid	Reference
rs1331924*	0.245	<i>ABCA1</i>	Lycopene	[59]
rs2791952*	0.140	<i>ABCA1</i>	Lycopene	[59]
rs3887137*	0.123	<i>ABCA1</i>	Lycopene	[59]
rs4149299*	0.082	<i>ABCA1</i>	Lycopene	[59]
rs4149316*	0.122	<i>ABCA1</i>	Lycopene	[59]
rs10248420	0.347	<i>ABCB1</i>	Lycopene	[59]
rs10280101	0.145	<i>ABCB1</i>	Lycopene	[59]
rs1871744	0.499	<i>ABCG2</i>	Lycopene	[59]
rs1042031*	0.153	<i>APOB</i>	Lycopene	[59]
rs4112274*	0.224	<i>CD36</i>	Lycopene	[59]
rs3798709	0.252	<i>ELOVL2</i>	Lycopene	[59]
rs911196	0.252	<i>ELOVL2</i>	Lycopene	[59]
rs9468304	0.302	<i>ELOVL2</i>	Lycopene	[59]
rs17006621*	0.172	<i>INSIG2</i>	Lycopene	[59]
rs2056983	0.117	<i>ISX</i>	Lycopene	[59]
rs12914035*	0.096	<i>LIPC</i>	Lycopene	[59]
rs8035357*	0.150	<i>LIPC</i>	Lycopene	[59]
rs17482753*	0.088	<i>LPL</i>	Lycopene	[59]
rs7005359*	0.298	<i>LPL</i>	Lycopene	[59]
rs7841189*	0.148	<i>LPL</i>	Lycopene	[59]
rs1032355	0.251	<i>MTTP</i>	Lycopene	[59]
rs17029173	0.135	<i>MTTP</i>	Lycopene	[59]
rs745075	0.095	<i>MTTP</i>	Lycopene	[59]
rs17725246	0.254	<i>NPC1L1</i>	Lycopene	[59]
rs935933	0.139	<i>PKD1L2</i>	Lycopene	[59]
rs11197742	0.087	<i>PNLIP</i>	Lycopene	[59]
rs10053477*	0.209	<i>SLC27A6</i>	Lycopene	[59]
rs9365046	0.169	<i>SOD2</i>	Lycopene	[59]

rs1929841	0.252	<i>ABCA1</i>	Lutein	[64]
rs174534	0.295	<i>FADS1</i>	Lutein	[64]
rs4926339	0.225	<i>RPE65</i>	Lutein	[64]
rs11057841	0.179	<i>SCARB1</i>	Lutein	[64]
rs4149316*	0.117	<i>ABCA1</i>	Lutein	[67]
rs390253*	0.257	<i>ABCA1</i>	Lutein	[67]
rs9919066*	0.063	<i>ABCA1</i>	Lutein	[67]
rs2020926*	0.105	<i>ABCA1</i>	Lutein	[67]
rs17731631	0.125	<i>ABCG2</i>	Lutein	[67]
rs6532059	0.047	<i>ABCG2</i>	Lutein	[67]
rs2070665*	0.180	<i>APOA1</i>	Lutein	[67]
rs2854725*	0.092	<i>APOB</i>	Lutein	[67]
rs3769877*	0.189	<i>COBLL1</i>	Lutein	[67]
rs9468304	0.309	<i>ELOVL2</i>	Lutein	[67]
rs3798709	0.250	<i>ELOVL2</i>	Lutein	[67]
rs17006621*	0.203	<i>INSIG2</i>	Lutein	[67]
rs2178704*	0.199	<i>IRS1</i>	Lutein	[67]
rs1316328*	0.142	<i>IRS1</i>	Lutein	[67]
rs137252	0.090	<i>ISX</i>	Lutein	[67]
rs137269	0.132	<i>ISX</i>	Lutein	[67]
rs5749706	0.199	<i>ISX</i>	Lutein	[67]
rs137238	0.122	<i>ISX</i>	Lutein	[67]
rs5755368	0.234	<i>ISX</i>	Lutein	[67]
rs12591216*	0.096	<i>LIPC</i>	Lutein	[67]
rs12593880*	0.075	<i>LIPC</i>	Lutein	[67]
rs1441778*	0.189	<i>LPL</i>	Lutein	[67]
rs7821631*	0.204	<i>LPL</i>	Lutein	[67]
rs10096561*	0.146	<i>LPL</i>	Lutein	[67]
rs256*	0.140	<i>LPL</i>	Lutein	[67]
rs11873337*	0.128	<i>MC4R</i>	Lutein	[67]

rs17029213	0.051	<i>MTTP</i>	Lutein	[67]
rs12596941	0.203	<i>PKD1L2</i>	Lutein	[67]
rs1924546	0.119	<i>RPE65</i>	Lutein	[67]
rs12934922	0.227	<i>BCO1</i>	β -carotene	[69], [58]
rs7501331	0.152	<i>BCO1</i>	β -carotene	[69], [58]
rs6420424	0.434	<i>BCO1</i>	β -carotene	[70]
rs11645428	0.156	<i>BCO1</i>	β -carotene	[70]
rs6564851	0.476	<i>BCO1</i>	β -carotene	[70]
rs2791952*	0.148	<i>ABCA1</i>	β -carotene	[71]
rs10991408*	0.127	<i>ABCA1</i>	β -carotene	[71]
rs3887137*	0.123	<i>ABCA1</i>	β -carotene	[71]
rs2278357	0.214	<i>ABCG5</i>	β -carotene	[71]
rs1042031*	0.153	<i>APOB</i>	β -carotene	[71]
rs4643493*	0.103	<i>APOB</i>	β -carotene	[71]
rs35364714*	0.127	<i>APOB</i>	β -carotene	[71]
rs7196470	0.244	<i>BCO1</i>	β -carotene	[71]
rs1247620	0.129	<i>CXCL8</i>	β -carotene	[71]
rs6834586	0.177	<i>CXCL8</i>	β -carotene	[71]
rs1358594	0.254	<i>CXCL8</i>	β -carotene	[71]
rs9468304	0.309	<i>ELOVL2</i>	β -carotene	[71]
rs3798709	0.252	<i>ELOVL2</i>	β -carotene	[71]
rs911196	0.251	<i>ELOVL2</i>	β -carotene	[71]
rs5755368	0.234	<i>ISX</i>	β -carotene	[71]
rs16994824	0.196	<i>ISX</i>	β -carotene	[71]
rs202313	0.142	<i>ISX</i>	β -carotene	[71]
rs1869138*	0.117	<i>LIPC</i>	β -carotene	[71]
rs11857380*	0.154	<i>LIPC</i>	β -carotene	[71]
rs12185072*	0.192	<i>LIPC</i>	β -carotene	[71]
rs8043708	0.227	<i>PKD1L2</i>	β -carotene	[71]
rs4926340	0.083	<i>RPE65</i>	β -carotene	[71]

rs12139131	0.102	<i>RPE65</i>	β-carotene	[71]
rs2501175	0.298	<i>SOD2</i>	β-carotene	[71]
rs946199*	0.173	<i>TCF7L2</i>	β-carotene	[71]

Abbreviations: ¹MAF: minor allele frequency

(<https://www.ncbi.nlm.nih.gov/projects/SNP/>); The gene official symbols are those found in PubMed (available online: <https://www.ncbi.nlm.nih.gov/gene/>) and approved by the Hugo Gene Nomenclature Committee (available online: <http://www.genenames.org/>). *These SNPs were associated with the variability of carotenoid bioavailability, but this was likely due to their association with the variability of the chylomicron triacylglycerol response [60].

REFERENCES AND RECOMMENDED READING

Papers of particular interest published during the review period (2015-2018) have been highlighted as:

* of special interest:

[2] This meta-analysis shows that tomato and lycopene supplementation are associated with improvement of cardiovascular disease risk factors.

[3] This meta-analysis shows that consumption of tomato foods and cooked tomatoes and sauces, but not that of raw tomatoes, is associated with a decrease in prostate cancer risk in a dose-dependent fashion.

[4] In this prospective follow-up studies, > 100,000 subjects were followed for ≈25 years.

[14] This study shows lycopene has partial provitaminA in mice.

[17] This is a nice demonstration of the effect of lycopene isomeric form on its bioavailability.

[33] This study shows SR-BI could have an indirect effect on fat-soluble vitamin and carotenoid uptake in the enterocyte by promoting chylomicron synthesis.

[38] This study shows that intestinal BCO2 is not significantly involved in postprandial conversion of newly absorbed β -carotene.

[40] This study refines the knowledge on the substrate specificity of BCO2.

[54] A nice demonstration of the protective effects of photoreceptors by carotenoids.

[62] This article highlights the interaction between omega-3 metabolism and carotenoid bioavailability.

[66] A nice demonstration of the origin of *meso*-zeaxanthin in the eye.

** of outstanding interest:

[29] An important study nicely demonstrating the regulation of SR-B1 and BCO1 activity by intracellular retinoic acid levels, with effects on both carotene and xanthophyll uptake and metabolism.

[52] This study proposes a new mechanisms to explain the differential accumulation of lutein and zeaxanthin in retinal pigment epithelial cells based on differences in blood lipoprotein transport.

[1] Reimers KJPRD, Keast DRP. Tomato Consumption in the United States and Its Relationship to the US Department of Agriculture Food Pattern: Results From What We Eat in America 2005-2010. *Nutrition Today* July/August 2016; 51:198-205.

[2] Cheng HM, Koutsidis G, Lodge JK *et al.* Tomato and lycopene supplementation and cardiovascular risk factors: A systematic review and meta-analysis. *Atherosclerosis* 2017; 257:100-108.

[3] Rowles JL, 3rd, Ranard KM, Applegate CC *et al.* Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose-response meta-analysis. *Prostate Cancer Prostatic Dis* 2018.

[4] Wu J, Cho E, Willett WC *et al.* Intakes of Lutein, Zeaxanthin, and Other Carotenoids and Age-Related Macular Degeneration During 2 Decades of Prospective Follow-up. *JAMA Ophthalmol* 2015; 133:1415-1424.

[5] Dorais M, Ehret DL, Papadopoulos AP. Tomato (*Solanum lycopersicum*) health components: from the seed to the consumer. *Phytochemistry Reviews* 2008; 7:231-250.

[6] Eggersdorfer M, Wyss A. Carotenoids in human nutrition and health. *Arch Biochem Biophys* 2018; 652:18-26.

[7] Stahl W, Sies H. Antioxidant activity of carotenoids. *Mol Aspects Med* 2003; 24:345-351.

[8] Bonet ML, Canas JA, Ribot J, Palou A. Carotenoids in Adipose Tissue Biology and Obesity. *Subcell Biochem* 2016; 79:377-414.

[9] Caris-Veyrat C, Garcia AL, Reynaud E *et al.* A Review About Lycopene-Induced Nuclear Hormone Receptor Signalling in Inflammation and Lipid Metabolism via still Unknown Endogenous Apo-10 -Lycopenoids. *Int J Vitam Nutr Res* 2017:1-9.

[10] Fenni S, Hammou H, Astier J *et al.* Lycopene and tomato powder supplementation similarly inhibit high-fat diet induced obesity, inflammatory response, and associated metabolic disorders. *Mol Nutr Food Res* 2017; 61.

[11] Gouranton E, Thabuis C, Riollot C *et al.* Lycopene inhibits proinflammatory cytokine and chemokine expression in adipose tissue. *J Nutr Biochem* 2011; 22:642-648.

[12] Landrier JF, Marcotrichino J, Tourniaire F. Lipophilic micronutrients and adipose tissue biology. *Nutrients* 2012; 4:1622-1649.

[13] Marcotrichino J, Romier B, Gouranton E *et al.* Lycopene attenuates LPS-induced TNF- α secretion in macrophages and inflammatory markers in adipocytes exposed to macrophage-conditioned media. *Mol Nutr Food Res* 2012; 56:725-732.

[14] Aydemir G, Kasiri Y, Bartok EM *et al.* Lycopene supplementation restores vitamin A deficiency in mice and possesses thereby partial pro-vitamin A activity transmitted via RAR signaling. *Mol Nutr Food Res* 2016; 60:2413-2420.

- [15] Gouranton E, Aydemir G, Reynaud E *et al.* Apo-10'-lycopenoic acid impacts adipose tissue biology via the retinoic acid receptors. *Biochim Biophys Acta* 2011; 1811:1105-1114.
- [16] Davies JN, Hobson GE. The constituents of tomato fruit--the influence of environment, nutrition, and genotype. *Crit Rev Food Sci Nutr* 1981; 15:205-280.
- [17] Cooperstone JL, Ralston RA, Riedl KM *et al.* Enhanced bioavailability of lycopene when consumed as cis-isomers from tangerine compared to red tomato juice, a randomized, cross-over clinical trial. *Mol Nutr Food Res* 2015; 59:658-669.
- [18] Bohn T, Desmarchelier C, Dragsted LO *et al.* Host-related factors explaining interindividual variability of carotenoid bioavailability and tissue concentrations in humans. *Mol Nutr Food Res* 2017; 61.
- [19] Desmarchelier C, Borel P. Overview of carotenoid bioavailability determinants: From dietary factors to host genetic variations. *Trends in Food Science & Technology* 2017; 69:270-280.
- [20] Borel P, Grolier P, Mekki N *et al.* Low and high responders to pharmacological doses of beta-carotene: proportion in the population, mechanisms involved and consequences on beta-carotene metabolism. *J Lipid Res* 1998; 39:2250-2260.
- [21] Reboul E, Borel P. Proteins involved in uptake, intracellular transport and basolateral secretion of fat-soluble vitamins and carotenoids by mammalian enterocytes. *Prog Lipid Res* 2011; 50:388-402.
- [22] Borel P, Desmarchelier C. Genetic Variations Associated with Vitamin A Status and Vitamin A Bioavailability. *Nutrients* 2017; 9:in press.
- [23] Borel P, Grolier P, Armand M *et al.* Carotenoids in biological emulsions: solubility, surface-to-core distribution, and release from lipid droplets. *J Lipid Res* 1996; 37:250-261.
- [24] Reboul E, Richelle M, Perrot E *et al.* Bioaccessibility of carotenoids and vitamin E from their main dietary sources. *J Agric Food Chem* 2006; 54:8749-8755.
- [25] Bohn T, McDougall GJ, Alegria A *et al.* Mind the gap-deficits in our knowledge of aspects impacting the bioavailability of phytochemicals and their metabolites--a position paper focusing on carotenoids and polyphenols. *Mol Nutr Food Res* 2015; 59:1307-1323.
- [26] Borel P, Lietz G, Goncalves A *et al.* CD36 and SR-BI are involved in cellular uptake of provitamin A carotenoids by Caco-2 and HEK cells, and some of their genetic variants are associated with plasma concentrations of these micronutrients in humans. *J Nutr* 2013; 143:448-456.
- [27] van Bennekum A, Werder M, Thuahnai ST *et al.* Class B scavenger receptor-mediated intestinal absorption of dietary beta-carotene and cholesterol. *Biochemistry* 2005; 44:4517-4525.
- [28] During A, Dawson HD, Harrison EH. Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. *Journal of Nutrition* 2005; 135:2305-2312.
- [29] Widjaja-Adhi MA, Lobo GP, Golczak M, Von Lintig J. A genetic dissection of intestinal fat-soluble vitamin and carotenoid absorption. *Hum Mol Genet* 2015; 24:3206-3219.
- [30] Moussa M, Landrier JF, Reboul E *et al.* Lycopene absorption in human intestinal cells and in mice involves scavenger receptor class B type I but not Niemann-Pick C1-like 1. *J Nutr* 2008; 138:1432-1436.
- [31] Moussa M, Gouranton E, Gleize B *et al.* CD36 is involved in lycopene and lutein uptake by adipocytes and adipose tissue cultures. *Mol Nutr Food Res* 2011; 55:578-584.
- [32] Sato Y, Suzuki R, Kobayashi M *et al.* Involvement of cholesterol membrane transporter Niemann-Pick C1-like 1 in the intestinal absorption of lutein. *J Pharm Pharm Sci* 2012; 15:256-264.

- [33] Briand O, Touche V, Colin S *et al.* Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1. *Gastroenterology* 2016; 150:650-658.
- [34] Tran TT, Poirier H, Clement L *et al.* Luminal lipid regulates CD36 levels and downstream signaling to stimulate chylomicron synthesis. *J Biol Chem* 2011; 286:25201-25210.
- [35] dela Sena C, Riedl KM, Narayanasamy S *et al.* The human enzyme that converts dietary provitamin A carotenoids to vitamin A is a dioxygenase. *J Biol Chem* 2014; 289:13661-13666.
- [36] Amengual J, Widjaja-Adhi MA, Rodriguez-Santiago S *et al.* Two carotenoid oxygenases contribute to mammalian provitamin A metabolism. *J Biol Chem* 2013; 288:34081-34096.
- [37] dela Sena C, Narayanasamy S, Riedl KM *et al.* Substrate specificity of purified recombinant human beta-carotene 15,15'-oxygenase (BCO1). *J Biol Chem* 2013; 288:37094-37103.
- [38] Kopec RE, Caris-Veyrat C, Nowicki M *et al.* Production of asymmetric oxidative metabolites of ¹³C β-carotene during digestion in the gastrointestinal lumen of healthy men. *Am J Clin Nutr* 2018; In press.
- [39] Richelle M, Sanchez B, Tavazzi I *et al.* Lycopene isomerisation takes place within enterocytes during absorption in human subjects. *Br J Nutr* 2010; 103:1800-1807.
- [40] Dela Sena C, Sun J, Narayanasamy S *et al.* Substrate Specificity of Purified Recombinant Chicken beta-Carotene 9',10'-Oxygenase (BCO2). *J Biol Chem* 2016; 291:14609-14619.
- [41] Lindshield BL, King JL, Wyss A *et al.* Lycopene biodistribution is altered in 15,15'-carotenoid monooxygenase knockout mice. *J Nutr* 2008; 138:2367-2371.
- [42] Ford NA, Elsen AC, Erdman JW, Jr. Genetic ablation of carotene oxygenases and consumption of lycopene or tomato powder diets modulate carotenoid and lipid metabolism in mice. *Nutr Res* 2013; 33:733-742.
- [43] Hu KQ, Liu C, Ernst H *et al.* The biochemical characterization of ferret carotene-9',10'-monooxygenase catalyzing cleavage of carotenoids in vitro and in vivo. *J Biol Chem* 2006; 281:19327-19338.
- [44] Tang G, Qin J, Dolnikowski GG, Russell RM. Short-term (intestinal) and long-term (postintestinal) conversion of beta-carotene to retinol in adults as assessed by a stable-isotope reference method. *Am J Clin Nutr* 2003; 78:259-266.
- [45] Wang Z, Yin S, Zhao X *et al.* beta-Carotene-vitamin A equivalence in Chinese adults assessed by an isotope dilution technique. *Br J Nutr* 2004; 91:121-131.
- [46] Lobo GP, Amengual J, Baus D *et al.* Genetics and diet regulate vitamin A production via the homeobox transcription factor ISX. *J Biol Chem* 2013; 288:9017-9027.
- [47] Lobo GP, Hessel S, Eichinger A *et al.* ISX is a retinoic acid-sensitive gatekeeper that controls intestinal beta,beta-carotene absorption and vitamin A production. *Faseb J* 2010; 24:1656-1666.
- [48] Dash S, Xiao C, Morgantini C, Lewis GF. New Insights into the Regulation of Chylomicron Production. *Annu Rev Nutr* 2015; 35:265-294.
- [49] Niesor EJ, Chaput E, Mary JL *et al.* Effect of compounds affecting ABCA1 expression and CETP activity on the HDL pathway involved in intestinal absorption of lutein and zeaxanthin. *Lipids* 2014; 49:1233-1243.
- [50] Dallinga-Thie GM, Kroon J, Boren J, Chapman MJ. Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? *Curr Cardiol Rep* 2016; 18:67.
- [51] Zaripheh S, Erdman JW, Jr. The biodistribution of a single oral dose of [¹⁴C]-lycopene in rats prefed either a control or lycopene-enriched diet. *J Nutr* 2005; 135:2212-2218.
- [52] Thomas SE, Harrison EH. Mechanisms of selective delivery of xanthophylls to retinal pigment epithelial cells by human lipoproteins. *J Lipid Res* 2016; 57:1865-1878.

- [53] Mares J. Lutein and Zeaxanthin Isomers in Eye Health and Disease. *Annu Rev Nutr* 2016; 36:571-602.
- [54] Widjaja-Adhi MAK, Ramkumar S, von Lintig J. Protective role of carotenoids in the visual cycle. *Faseb J* 2018:fj201800467R.
- [55] Borel P. Genetic variations involved in interindividual variability in carotenoid status. *Mol Nutr Food Res* 2012; 56:228-240.
- [56] Moran NE, Erdman JW, Jr., Clinton SK. Complex interactions between dietary and genetic factors impact lycopene metabolism and distribution. *Arch Biochem Biophys* 2013; 539:171-180.
- [57] Borel P, Desmarchelier C. Bioavailability of Fat-Soluble Vitamins and Phytochemicals in Humans: Effects of Genetic Variation. *Annu Rev Nutr* 2018; 38:In press.
- [58] Wang TT, Edwards AJ, Clevidence BA. Strong and weak plasma response to dietary carotenoids identified by cluster analysis and linked to beta-carotene 15,15'-monooxygenase 1 single nucleotide polymorphisms. *J Nutr Biochem* 2013; 24:1538-1546.
- [59] Borel P, Desmarchelier C, Nowicki M, Bott R. Lycopene bioavailability is associated with a combination of genetic variants. *Free Radic Biol Med* 2015; 83:238-244.
- [60] Desmarchelier C, Martin JC, Planells R *et al.* The postprandial chylomicron triacylglycerol response to dietary fat in healthy male adults is significantly explained by a combination of single nucleotide polymorphisms in genes involved in triacylglycerol metabolism. *J Clin Endocrinol Metab* 2014; 99:E484-488.
- [61] Margier MC, X.; le May, C.; Desmarchelier, C.; André, F.; Bluteau, A.; Defoort, C.; Borel, P.; Lespine, A.; Reboul, E. ABCB1 (P-glycoprotein) regulates vitamin D absorption and contributes to its transintestinal efflux. *Faseb J* 2018; In Press.
- [62] Mashurabad PC, Kondaiah P, Palika R *et al.* Eicosapentaenoic acid inhibits intestinal beta-carotene absorption by downregulation of lipid transporter expression via PPAR-alpha dependent mechanism. *Arch Biochem Biophys* 2016; 590:118-124.
- [63] Tong SY, Lee JM, Song ES *et al.* Functional polymorphism in manganese superoxide dismutase and antioxidant status: their interactions on the risk of cervical intraepithelial neoplasia and cervical cancer. *Gynecol Oncol* 2009; 115:272-276.
- [64] Yonova-Doing E, Hysi PG, Venturini C *et al.* Candidate gene study of macular response to supplemental lutein and zeaxanthin. *Exp Eye Res* 2013; 115:172-177.
- [65] Duncan KG, Hosseini K, Bailey KR *et al.* Expression of reverse cholesterol transport proteins ATP-binding cassette A1 (ABCA1) and scavenger receptor BI (SR-BI) in the retina and retinal pigment epithelium. *Br J Ophthalmol* 2009; 93:1116-1120.
- [66] Shyam R, Gorusupudi A, Nelson K *et al.* RPE65 has an additional function as the lutein to meso-zeaxanthin isomerase in the vertebrate eye. *Proc Natl Acad Sci U S A* 2017.
- [67] Borel P, Desmarchelier C, Nowicki M *et al.* Interindividual variability of lutein bioavailability in healthy men: characterization, genetic variants involved, and relation with fasting plasma lutein concentration. *Am J Clin Nutr* 2014; 100:168-175.
- [68] Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). *Curr Drug Metab* 2010; 11:603-617.
- [69] Leung WC, Hessel S, Meplan C *et al.* Two common single nucleotide polymorphisms in the gene encoding beta-carotene 15,15'-monooxygenase alter beta-carotene metabolism in female volunteers. *Faseb J* 2009; 23:1041-1053.
- [70] Lietz G, Oxley A, Leung W, Hesketh J. Single Nucleotide Polymorphisms Upstream from the beta-Carotene 15,15'-Monooxygenase Gene Influence Provitamin A Conversion Efficiency in Female Volunteers. *J Nutr* 2012; 142:161S-165S.
- [71] Borel P, Desmarchelier C, Nowicki M, Bott R. A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Dietary beta-Carotene Bioavailability in Healthy Men. *J Nutr* 2015; 145:1740-1747.

Figure